Zobrazeno 1 - 10 of 190 pro vyhledávání: '"H.H. Fiebig"'
2
Pharmacokinetic and Pharmacodynamic Study with Lobaplatin (D-19466), a New Platinum Complex, after Bolus Administration
Autor: H.H. Fiebig, U. Hieber, Klaus Mross, F. Meyberg, P. Aulenbacher, K. Hamm, D.K. Hossfeld
Publikováno v: Oncology Research and Treatment. 15:139-146
Background: Lobaplatin (D-19466) is a platinum compound with greater anticancer activity in NSCLC, stomach, breast and ovarian cancer in the human tumor xeno-graft model. Preclinica
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71c916296edd3d0c441e07bcfddedab1
https://doi.org/10.1159/000217347
Zobrazit plný text záznamu
3
Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents
Autor: A. Hussain, H.H. Fiebig, G.J. Peters, F. Dai, V. Smith, M. Spitz, A.M. Burger
Publikováno v: Journal of chemotherapy, 21(5), 542-549. Maney Publishing
Smith, V, Dai, F, Spitz, M, Peters, G J, Fiebig, H H, Hussain, A & Burger, A W 2009, ' Telomerase Activity and Telomere Length in Human Tumor Cells with Acquired Resistance to Anticancer Agents ', Journal of chemotherapy, vol. 21, no. 5, pp. 542-549 . https://doi.org/10.1179/joc.2009.21.5.542
Telomeres and telomerase are targets for anticancer drug development and specific inhibitors are currently under clinical investigation. However, it has been reported that standard cytotoxic agents can affect telomere length and telomerase activity s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef86455e70dc94801b3ecc99bc57283e
https://research.vumc.nl/en/publications/f9c059cc-9dd4-4793-9874-d67385492de2
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
Autor: Axel-R. Hanauske, Wolfgang E. Berdel, Ch. Manegold, K. Burk, A. Kaeser-Fröhlich, Andreas Hüttmann, Rassmann I, H.H. Fiebig, R. Thödtmann, M. Mross
Publikováno v: Investigational new drugs. 16(4)
Background: NK611 is a novel podophyllotoxin derivative. Compared with etoposide, NK611 carries a dimethyl-amino group at the D-glucose moiety. The antitumor activity of NK611 showed to be equal or superior to etoposide in a variety of in vitro and i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd52e1399de4652a18a023cb368cac9c
https://pubmed.ncbi.nlm.nih.gov/10426664
Zobrazit plný text záznamu
7
Enhancement of a constitutively active promoter for gene therapy by a positive feed-back transcriptional activator mechanism
Autor: Hendrik Veelken, Albrecht Lindemann, B Leutgeb, H.H. Fiebig, Peter Kulmburg, Andreas Mackensen
Publikováno v: Scopus-Elsevier
Success of gene replacement therapy depends on long-term, high level expression of the transgene. Gene therapy vectors incorporating a promoter of a constitutively active eukaryotic gene may allow long-term expression in vivo, but the expression leve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb0b9972fd75637e07386ca1abb9a33
https://pubmed.ncbi.nlm.nih.gov/9857228
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje